CELYAD
CELYAD
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multip... le myeloma; and CYAD-02, an autologous CAR-T therapy that is in Phase 1 clinical trial for the treatment of hematological malignancies and solid tumors. The company's preclinical candidates, include allogeneic CAR-T candidate for the treatment of solid tumors; CYAD-221, shRNA based allogeneic CAR-T candidate to treat B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting natural killer group 2D ligands (NKG2D) and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Industry:
Organization
Founded:
2007
Address:
Axis Business Park, Mont-Saint-Guibert, Belgium Zipcode 1435
Country:
United Kingdom
Phone:
32 1 039 41 00
Market Cap:
73.01MTotal Revenue:
5kTotal Assets:
66.08MTotal Cash:
17.23M
Website Url:
http://www.celyad.com
Key Executives
| Name | Title | Pay | Year Born |
|---|---|---|---|
| Mr. Michel E. J. Lussier BME, M.B.A., M.S., MS BME, MBA | Co-Founder & Chairman | 70,000$ | 1956(64 years old) |
| Mr. Filippo Joseph Petti | CEO, CFO & Director | 625,126$ | 1976(44 years old) |
| Dr. David Edward Gilham | Chief Scientific Officer | N/A | 1965(55 years old) |
| Sara Zelkovic | Communications & Investor Relations Director | N/A | N/A |
| Mr. Philippe Dechamps | Chief Legal Officer & Corp. Sec. | N/A | 1970(50 years old) |
| Mr. Philippe Nobels | Chief HR Officer & VP of HR | N/A | 1966(54 years old) |
| Dr. Stephen Rubino M.B.A., Ph.D. | Chief Bus. Officer | N/A | 1958(62 years old) |
| Dr. Elena Spanjaard | Head of Global Quality & Regulatory | N/A | N/A |
| Dr. Peggy Sotiropoulou | Head of R&D | N/A | N/A |
| Mr. Thomas Lequertier | Head of Cell Therapy Manufacturing Unit | N/A | N/A |
Financial & Stock
Company's stock symbol is 0QFK.L. Lastest price : 6.02. Total volume :3.02k Click reload if you want to check the lastest price on market!!!
Site Inspections: http://www.celyad.com
- Host name: 109.230.214.35.bc.googleusercontent.com
- IP address: 35.214.230.109
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Celyad" on Search Engine
Home - Celyad Oncology
Celyad.com Apr 01, 2021 · Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. More Info About Celyad ONCOLOGY. Latest News. Celyad Oncology Announces April 2021 Conference Schedule. April 1, 2021
Home - Celyad Oncology
Celyad.com CYAD-101 is an investigational, non-gene edited allogeneic (from healthy donor …
Home - Celyad Oncology
Celyad.com Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene …
Home - Celyad Oncology
Celyad.com Contact Us get in Touch Belgium Axis Business Park Rue Edouard Belin 2 1435 …
Home - Celyad Oncology
Celyad.com Sotiropoulou joined Celyad Oncology initially as R&D Manager, evolving to R&D Director in …
Home - Celyad Oncology
Celyad.com Celyad Oncology is a clinical-stage biotechnology company focused on the …
Home - Celyad Oncology
Celyad.com At Celyad Oncology, we are evaluating both allogeneic and autologous CAR T therapy …
Home - Celyad Oncology
Celyad.com Encoding multiple components of the CAR T construct, including the chimeric antigen …
Home - Celyad Oncology
Celyad.com Celyad Announces Third Quarter 2019 Financial Results and Recent Business …
Home - Celyad Oncology
Celyad.com Celyad Oncology is looking for a Quality Specialist. The successful candidate will be …
Home - Celyad Oncology
Celyad.com Minutes of shareholders meeting of 23 March 2020 Convening notice to shareholders …
Celyad Oncology SA (CYAD) Stock Price, News, Quote
Finance.yahoo.com About Celyad Oncology Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
CYAD Stock Price | Celyad Oncology S.A. ADR Stock Quote (U)
Marketwatch.com Apr 09, 2021 · Celyad Oncology SA engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno …
Celyad | Edison
Edisongroup.com Feb 01, 2020 · Celyad is developing an innovative Natural Killer Receptor CAR T-cell therapy (CYAD-01). This focuses on AML and metastatic colorectal cancer. …
Celyad to Present Update from CYAD-101 for Advanced
Finance.yahoo.com Apr 30, 2020 · Celyad to Present Update from CYAD-101 for Advanced Colorectal Cancer and Next-Generation shRNA Platform at 2020 ASCO Virtual Scientific Program Two accepted abstracts will …
Celyad Company Profile - Office Locations, Competitors
Craft.co Jun 01, 2020 · Celyad is a biopharmaceutical company, specialized in cell therapy and developing of technologies to treat severe diseases with poor prognosis. The Company focuses on immuno oncology, cardiology, and medical devices.
Celyad Highlights Safety and Clinical Activity of CYAD-101
Bloomberg.com Nov 11, 2019 · Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and …
Driving the future of CAR-T cell therapies
Nature.com Celyad’s shRNA platform is the result of an exclusive agreement with Horizon Discovery Group for the use of its subsidiary Dharmacon’s SMARTvector shRNA technology. In the allogeneic setting ...
Celyad’s CAR T-Cell Therapy, CYAD-01, Showing Early Signs
Immuno-oncologynews.com Nov 20, 2018 · CYAD-01 — Celyad ‘s CAR T-cell product — is showing promise as a treatment for metastatic colorectal cancer patients (mCRC), both alone and in combination with standard of care chemotherapy, according to findings from two clinical trials.
Celyad Inc. Company Profile | Boston, MA | Competitors
Dnb.com Celyad Inc. is located in Boston, MA, United States and is part of the Pharmaceutical Manufacturing Industry. Celyad Inc. has 8 total employees across all of its …
Celyad to Begin Phase 1 Trial of Donor-derived CAR T-cell
Myelomaresearchnews.com Jul 31, 2020 · The U.S. Food and Drug Administration (FDA) has given Celyad Oncology permission to begin a Phase 1 clinical trial of CYAD-211, an investigational treatment for relapsed or refractory multiple myeloma.The trial is expected to commence by year’s end. “The FDA’s permission to begin the Phase 1 clinical trial of our lead shRNA-based allogeneic candidate CYAD-211 is a watershed moment for ...
Celyad Oncology Announces April 2021 Conference Schedule
Markets.businessinsider.com Apr 01, 2021 · Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
CYAD Stock Forecast, Price & News (Celyad Oncology)
Marketbeat.com Earnings for Celyad Oncology are expected to grow in the coming year, from ($2.85) to ($2.06) per share. Price to Earnings Ratio vs. the Market. The P/E ratio of Celyad Oncology is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Price to Earnings Ratio vs. Sector
Celyad Rebrands as Celyad Oncology Nasdaq:CYAD
Globenewswire.com Jun 10, 2020 · Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of ...
Celyad Oncology Discontinues Autologous CAR T Candidate
Nasdaq.com Dec 07, 2020 · (RTTNews) - Celyad Oncology SA (CYAD), a clinical-stage biotechnology company focused on chimeric antigen receptor T cell or CAR T therapies …
Celyad - Crunchbase Company Profile & Funding
Crunchbase.com Jun 30, 2016 · Celyad is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T …
Celyad: The Second Wave (NASDAQ:CYAD) | Seeking Alpha
Seekingalpha.com Celyad is pioneering an effort to make CAR-T therapy work in solid tumors. This is a big deal because CAR-T, a very successful new cancer therapy, has traditionally only targeted blood cancers....
Celyad Provides Update on Allogeneic CAR-T Franchise
Businesswire.com Celyad Filippo Petti, Chief Executive Officer – [email protected] Alexandrine Hazard, Communications & IR Associate – T: +32(0) 10 39 41 58 – [email protected]
Fate Therapeutics' and Celyad’s CAR therapies in oncology
Pharmaceutical-technology.com Celyad’s allogeneic CYAD-101 is being tested in a Phase I alloSHRINK trial (NCT03692429) in metastatic colorectal cancer (CRC), which has a primary completion date of November 2020. FT596’s sales are expected to reach $136m in 2026, according to a GlobalData Consensus forecast. Celyad did not respond to a request for comment.
A Dose Escalation Phase I Study to Assess the Safety and
Clinicaltrials.gov Jan 12, 2017 · Celyad Oncology SA: ClinicalTrials.gov Identifier: NCT03018405 Other Study ID Numbers: CYAD-N2T-002 : First Posted: January 12, 2017 Key Record Dates: Last Update Posted: September 19, 2019 Last Verified: November 2018 Individual Participant Data …
Celyad Oncology Announces April 2021 Conference Schedule
Streetinsider.com Apr 01, 2021 · Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
Celyad Oncology's (CYAD) CEO Filippo Petti on Q4 2020
Seekingalpha.com Mar 26, 2021 · Celyad Oncology SA (NASDAQ:CYAD) Q4 2020 Earnings Conference Call March 25, 2021 8:00 AM ET. Company Participants. Filippo Petti – …
Celyad's novel CAR T-cell therapy for solid malignancies
Sciencedirect.com May 01, 2018 · Celyad has developed a CAR construct based on the full-length natural killer group 2D (NKG2D) receptor fused with the CD3ζ signaling domain, called CYAD-01 (a.k.a. NKR-2). NKG2D is an innate immune activating receptor expressed in humans mainly by natural killer (NK) ...
| live
Live.euronext.com Celyad : Information relative au Nombre Total de Droits de Vote et d’Actions (Article 15 de la Lo... 24/03/2021 Celyad Oncology présente ses résultats financiers …
FDA OKs Phase 1 Trial to Test Celyad’s Donor-derived CAR T
Immuno-oncologynews.com Aug 01, 2018 · Celyad will soon begin clinical development of its immunotherapy CYAD-101 (CAR-T NKG2D) and evaluate its potential as a treatment for patients with colorectal cancer that cannot be surgically removed.. The first-in-human Phase 1 trial, called Allo-SHRINK, comes after the approval of an investigational new drug application for CYAD-101 by the U.S. Food and Drug Administration.
CYAD - Celyad Oncology SA • BioPharmCatalyst
Biopharmcatalyst.com MONT-SAINT-GUIBERT, Belgium, March 18, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will report full year 2020 financial and operating results on the evening of Wednesday, …
Celyad Oncology Announces Clinical Trial Collaboration to
Markets.businessinsider.com Sep 29, 2020 · Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of ...
Celyad Oncology | LinkedIn
Linkedin.com About us Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
Celyad is a clinical-stage biopharmaceutical company
Thepharmaletter.com Celyad is a clinical-stage biopharmaceutical company focused on the identification and development of specialized cell-based therapies. Founded in 2007, Celyad seeks to address diseases with high unmet medical needs such as heart failure and cancer.
Celyad: Information on the Total Number of Voting Rights
Streetinsider.com Mar 31, 2021 · Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
COVID shows plus of inhouse, Celyad - Bioprocess
Bioprocessintl.com Correction: The original article stated Celyad’s inhouse facility is located in Rochester, Minnesota when in fact the facility is in Mont-Saint-Guibert, Belgium. the firm had announced a site in Minnesota in 2015 but since changed plans. Categories: BioProcess Insider, Therapeutic Class.
Celyad Oncology Appoints Marina Udier, Ph.D., to Board of
Globenewswire.com Jan 11, 2021 · About Celyad Oncology Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T …
Celyad Oncology Presents Data Update from Phase 1
Nasdaq.com Jan 18, 2021 · Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
What Makes Celyad SA (CYAD) a New Buy Stock - March 31
Zacks.com Mar 31, 2020 · Earnings Estimate Revisions for Celyad SA For the fiscal year ending December 2020, this company is expected to earn -$2.63 per share, which is a change of -2.3% from the year-ago reported number.
CYAD:EN Brussels Stock Quote - Celyad Oncology SA
Bloomberg.com Celyad Oncology SA is a bio-pharmaceutical company. The Company specialized in CAR-T cell therapy, that is developing landmark technologies aimed at treating severe diseases with poor prognosis ...
alloSHRINK - Standard cHemotherapy Regimen and
Clinicaltrials.gov Oct 02, 2018 · Celyad Oncology SA: ClinicalTrials.gov Identifier: NCT03692429 Other Study ID Numbers: CYAD-N2L-101 : First Posted: October 2, 2018 Key Record Dates: Last Update Posted: November 20, 2020 Last Verified: November 2020 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No
Working at Celyad | Glassdoor
Glassdoor.com Glassdoor gives you an inside look at what it's like to work at Celyad, including salaries, reviews, office photos, and more. This is the Celyad company profile. All content is posted anonymously by employees working at Celyad.
CYAD Celyad — Stock Price and Discussion | Stocktwits
Stocktwits.com Apr 09, 2021 · Celyad NASDAQ Updated Apr 9, 2021 7:58 PM. CYAD 6.96 0.05 (0.71%). 479
Celyad's High Hopes for a Path Forward in Cancer
Biospace.com Sep 02, 2020 · Celyad Oncology is at the forefront of cutting-edge immunotherapy and is hopeful of providing a new way forward for patients with relapsed/refractory multiple myeloma. After receiving FDA approval on July 14 th to begin Phase I trials, they plan to be …
Celyad Oncology (ENXTBR:CYAD) - Share price, News
Simplywall.st Celyad Oncology, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of cancer. More Details. Rewards. Revenue is forecast to grow 30.43% per year. Risk Analysis. Earnings are forecast to …
Celyad's Novel CAR T-cell Therapy for Solid Malignancies
Pubmed.ncbi.nlm.nih.gov Celyad recently initiated several clinical trials with the CYAD-01 product, a natural killer group 2D (NKG2D)-based chimeric antigen receptor (CAR), in both solid and hematologic tumor types. This review discusses the unique properties of CYAD-01, expecting to provide a new paradigm to fight against …
Celyad Oncology Company Profile: Stock Performance
Pitchbook.com Celyad Oncology General Information Description. Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure.
All You Need to Know About Celyad SA (CYAD) Rating Upgrade
Zacks.com May 25, 2020 · Celyad SA (CYAD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in …
Next Generation NKG2D-based CAR T-cells (CYAD-02): Co
Ashpublications.org Nov 13, 2019 · Fontaine:Celyad: Employment.Demoulin:Celyad: Employment.Bornschein:Celyad: Employment.Raitano:Celyad: Employment.Machado:Horizon Discovery: Employment.Moore:Avvinity ...
Celyad Oncology to Present Updates from Allogeneic and
Markets.ft.com Nov 04, 2020 · Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com. Forward-looking statements
CYAD Price Target, Analyst Ratings and Predictions (Celyad)
Marketbeat.com Jun 02, 2020 · 3 Wall Street analysts have issued ratings and price targets for Celyad Oncology in the last 12 months. Their average twelve-month price target is $18.00, predicting that the stock has a possible upside of 156.78%. The high price target for CYAD is $18.00 and the low price target for CYAD is …
Celyad Oncology Announces April 2021 Conference Schedule
Apnews.com Apr 01, 2021 · Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com. Forward-Looking Statement
CYAD - Stock quote for Celyad Oncology - MSN Money
Msn.com Celyad Oncology Reports Full Year 2020 Financial Results and Recent Business Highlights Yahoo Finance 3/24/2021. Myocardial Infarction Drug Market Supply, Sales, Revenue and …